Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection

Gastroenterology

Volumn 120, Issue 4, 2001, Pages 1000-1008

  Doo, E ^a   Liang, T J ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; ISOLEUCINE; LAMIVUDINE; METHIONINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TYROSINE; VALINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING SITE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; VIRUS GENE; VIRUS MUTANT; VIRUS REPLICATION;

EID: 0035120228     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.22454     Document Type: Article

References (55)

1. Hepatitis B
2. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: A meta-analysis
3. Lamivudine as initial treatment for chronic hepatitis B in the United States
4. A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group
5. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
6. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
7. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis
8. Hepatitis B virus biology
9. Hepadnaviridae and their replication
10. Carboxypeptidase D is an avian hepatitis B virus receptor
11. Carboxypeptidase D (gp 180), a Golgi-resident protein, functions in the attachment and entry of avian hepatitis B viruses
12. Hsp90 is required for the activity of a hepatitis b virus reverse transcriptase
13. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids
14. Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis
15. Relationship between viral DNA synthesis and virion envelopment in hepatitis B virus
16. Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy
17. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B
18. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
19. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids
20. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase
21. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements
22. dNTP binding to HIV-1 reverse transcriptase and mammalian DNA polymerase beta as revealed by affinity labeling with a photoreactive dNTP analog
23. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 angstrom resolution shows bent DNA
24. Structure of a covalently trapped catalytica complex of HIV-1 reverse transcriptase: Implications for drug resistance
25. Structure of unliganded HIV-1 reverse transcriptase at 2.7 anstrom resolution: Implications of conformational changes for polymerization and inhibition mechanisms
26. Identification of more than one mutation in the hepatitis B virus polymerase arising during prolonged lamivudine treatment
27. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns
28. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
29. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
30. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
31. Structural basis of HBV resistance to lamivudine and emtricitabine
32. Initial appearance of the 184lle variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase
33. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G→A hypermutation
34. Hepatitis delta virus: RNA editing and genotype variations
35. Molecular cloning of an apolipoprotein B messenger RNA editing protein
36. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
37. Replication fitness of hepatitis B virus polymerase mutants after antiviral treatment following liver transplantation
38. Reverse transcriptases and genomic variability: The accuracy of DNA replication is enzyme specific and sequence dependent
39. Dynamics of hepatitis B virus infection in vivo
40. Viral dynamics in hepatitis B virus infection
41. The clinical significance of molecular variation within the hepatitis B virus genome
42. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections
43. Low dynamic state of viral competition in a chronic avian hepadnavirus infection
44. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine
45. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
46. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus
47. Hepatitis B virus
48. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
49. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
50. Hepatitis B virus immunopathogenesis
51. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells
52. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis
53. For the Asian Hepatitis Lanivudine Trial Group. Pretherapy alanine transaminase level as determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
54. In vitro toxicity of 2′,3′-dideoxy-3′-thiacytidine (BCH189/3TC), a new synthetic anti-HIV-1 agent
55. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B